Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2009 1
2021 2
2022 6
2023 5
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Filters applied: . Clear all
Page 1
Sensitivity of anti-SARS-CoV-2 nucleocapsid protein antibody for breakthrough infections during the epidemic of the Omicron variants.
Mizoue T, Yamamoto S, Konishi M, Oshiro Y, Inamura N, Nemoto T, Ozeki M, Horii K, Okudera K, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. Mizoue T, et al. Among authors: ozeki m. J Infect. 2022 Nov;85(5):573-607. doi: 10.1016/j.jinf.2022.08.015. Epub 2022 Aug 20. J Infect. 2022. PMID: 35995310 Free PMC article. No abstract available.
Seroprevalence of SARS-CoV-2 antibodies in a national hospital and affiliated facility after the second epidemic wave of Japan.
Yamamoto S, Tanaka A, Oshiro Y, Ishii M, Ishiwari H, Konishi M, Matsuda K, Ozeki M, Miyo K, Maeda K, Mizoue T, Sugiura W, Mitsuya H, Sugiyama H, Ohmagari N. Yamamoto S, et al. Among authors: ozeki m. J Infect. 2021 Aug;83(2):237-279. doi: 10.1016/j.jinf.2021.05.017. Epub 2021 May 25. J Infect. 2021. PMID: 34044036 Free PMC article. No abstract available.
Coronavirus Disease 2019 (COVID-19) Breakthrough Infection and Post-Vaccination Neutralizing Antibodies Among Healthcare Workers in a Referral Hospital in Tokyo: A Case-Control Matching Study.
Yamamoto S, Maeda K, Matsuda K, Tanaka A, Horii K, Okudera K, Takeuchi JS, Mizoue T, Konishi M, Ozeki M, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: ozeki m. Clin Infect Dis. 2022 Aug 24;75(1):e683-e691. doi: 10.1093/cid/ciab1048. Clin Infect Dis. 2022. PMID: 34950947 Free PMC article.
Durability and determinants of anti-SARS-CoV-2 spike antibodies following the second and third doses of mRNA COVID-19 vaccine.
Yamamoto S, Oshiro Y, Inamura N, Nemoto T, Horii K, Okudera K, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: ozeki m. Clin Microbiol Infect. 2023 Sep;29(9):1201.e1-1201.e5. doi: 10.1016/j.cmi.2023.05.020. Epub 2023 May 24. Clin Microbiol Infect. 2023. PMID: 37236545 Free PMC article.
Neutralizing antibodies after three doses of the BNT162b2 vaccine, breakthrough infection, and symptoms during the Omicron-predominant wave.
Yamamoto S, Matsuda K, Maeda K, Horii K, Okudera K, Oshiro Y, Inamura N, Takeuchi JS, Konishi M, Ozeki M, Mizoue T, Sugiyama H, Aoyanagi N, Mitsuya H, Sugiura W, Ohmagari N. Yamamoto S, et al. Among authors: ozeki m. Int J Infect Dis. 2023 Mar;128:347-354. doi: 10.1016/j.ijid.2023.01.023. Epub 2023 Jan 22. Int J Infect Dis. 2023. PMID: 36693493 Free PMC article.
13 results